Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore Pincus

Showing results (91-100 of 202) with videos related to

Pageof 21
Sort By:
Clinical and Experimental Rheumatology|October 3, 2017
Assessment of pain and other patient symptoms in routine clinical care as quantitative, standardised, "scientific" dataJacquelin R Chua, Isabel Castrejon, Theodore Pincus
Bulletin of the NYU Hospital for Joint Diseases|July 9, 2009
RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseasesTheodore Pincus, Martin J Bergman, Yusuf Yazici
Current Rheumatology Reports|November 10, 2006
Improving survival in inflammatory rheumatic diseases: a neglected goal?Theodore Pincus, Allan Gibofsky, J Timothy Harrington
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 15, 2013
MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritisIsabel Castrejón, Martin J Bergman, Theodore Pincus
Rheumatology (Oxford, England)|March 29, 2025
Elevated DAS28, CDAI, RAPID3, and 5/7 RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQTheodore Pincus, Tengfei Li, Kathryn A Gibson
Bulletin of the Hospital for Joint Disease (2013)|August 24, 2014
RHEUMDOC: a one-page RHEUMatology DOCtor form with four physician global estimates for overall status, inflammation, damage, and symptoms based on neither inflammation nor damageMartin J Bergman, Isabel Castrejón, Theodore Pincus
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
Update on methotrexate as the anchor drug for rheumatoid arthritisTheodore Pincus, Kathryn A Gibson, Isabel Castrejón
ACR Open Rheumatology|May 20, 2025
Should Joint Deformity, which is More Common Than Swelling or Tenderness, be Assessed in all Rheumatoid Arthritis Patients and Databases?Theodore Pincus, Tengfei Li, Kathryn A Gibson
The Journal of Rheumatology|April 5, 2011
Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptomsAnca Dinu Askanase, Isabel Castrejón, Theodore Pincus
Clinical and Experimental Rheumatology|October 17, 2015
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?Theodore Pincus, Martin J Bergman, Yusuf Yazici
Pageof 21

Showing results (91-100 of 202) with videos related to

Sort By:
Pageof 21
Clinical and Experimental Rheumatology|October 3, 2017
Assessment of pain and other patient symptoms in routine clinical care as quantitative, standardised, "scientific" dataJacquelin R Chua, Isabel Castrejon, Theodore Pincus
Bulletin of the NYU Hospital for Joint Diseases|July 9, 2009
RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseasesTheodore Pincus, Martin J Bergman, Yusuf Yazici
Current Rheumatology Reports|November 10, 2006
Improving survival in inflammatory rheumatic diseases: a neglected goal?Theodore Pincus, Allan Gibofsky, J Timothy Harrington
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 15, 2013
MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritisIsabel Castrejón, Martin J Bergman, Theodore Pincus
Rheumatology (Oxford, England)|March 29, 2025
Elevated DAS28, CDAI, RAPID3, and 5/7 RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQTheodore Pincus, Tengfei Li, Kathryn A Gibson
Bulletin of the Hospital for Joint Disease (2013)|August 24, 2014
RHEUMDOC: a one-page RHEUMatology DOCtor form with four physician global estimates for overall status, inflammation, damage, and symptoms based on neither inflammation nor damageMartin J Bergman, Isabel Castrejón, Theodore Pincus
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
Update on methotrexate as the anchor drug for rheumatoid arthritisTheodore Pincus, Kathryn A Gibson, Isabel Castrejón
ACR Open Rheumatology|May 20, 2025
Should Joint Deformity, which is More Common Than Swelling or Tenderness, be Assessed in all Rheumatoid Arthritis Patients and Databases?Theodore Pincus, Tengfei Li, Kathryn A Gibson
The Journal of Rheumatology|April 5, 2011
Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptomsAnca Dinu Askanase, Isabel Castrejón, Theodore Pincus
Clinical and Experimental Rheumatology|October 17, 2015
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?Theodore Pincus, Martin J Bergman, Yusuf Yazici
Pageof 21